EYAL TALOR, PH.D. - Corporate Board Profile

CEL SCI CORP

Filing Date	Source Excerpt
2011-02-18	Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer.
2013-05-10	Eyal Talor, Ph.D. 56 Chief Scientific Officer ... Compensation of Directors During Year Ended September 30, 2012 (Only directors listed in the compensation of directors table, Eyal is not listed there.)
2015-04-21	Eyal Talor, Ph.D. 58 Chief Scientific Officer
2016-06-09	Eyal Talor, Ph.D. 60 Chief Scientific Officer
2017-04-27	Eyal Talor, Ph.D. 60 Chief Scientific Officer Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Compensation Table Eyal Talor, Ph.D., 2016 303,597 -- 9,600 -- 6,031 319,227 Chief Scientific 2015 290,983 -- 9,600 -- 6,031 306,613 Officer 2014 283,283 -- 1,731,290 55,278 6,031 2,075,882
2018-08-08	Name: Eyal Talor, Ph.D., Age: 62, Position: Chief Scientific Officer, No director compensation listed for Eyal Talor in the Directors’ fees table.
2019-03-26	Eyal Talor, Ph.D. 63 Chief Scientific Officer ... No director compensation listed for Eyal Talor.
2020-03-04	Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 25 years of hands-on management of clinical research and drug development for immunotherapy application; pre-clinical to Phase III, in the biopharmaceutical industry. His expertise includes; biopharmaceutical R&D and Biologics product development, GMP (Good Manufacturing Practices) manufacture, Quality Control testing, and the design and building of GMP manufacturing and testing facilities. He served as Director of Clinical Laboratories (certified by the State of Maryland) and has experience in the design of pre-clinical and clinical trials (Phase I – III) and GCP (Good Clinical Practices) requirements. He also has broad experience in the different aspects of biological assay development, analytical methods validation, raw material specifications, and QC (Quality Control) tests development under FDA/GMP, USP, and ICH guidelines. He has extensive experience in the preparation of documentation for IND and other regulatory submissions. His scientific area of expertise encompasses immune response assessment. He is the author of over 25 publications and has published a number of reviews on immune regulations in relation to clinical immunology. Before coming to CEL-SCI, he was Director of R&D and Clinical Development at CBL, Inc., Principal Scientist - Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. Prior to that he was a full time faculty member at The Johns Hopkins University, Medical Institutions; School of Public Health. He has invented technologies which are covered by ten issued patents on Multikine’s composition of matter and method of use in cancer and two platform Peptide technologies, Antigen Directed Apoptosis of T-cells (‘Adapt’) and LEAPS, for the treatment of autoimmune diseases, asthma, allergy, transplantation rejection and infectious diseases. He also is responsible for numerous product and process inventions as well as a number of pending US and PCT patent applications. He received his Ph.D. in Microbiology and Immunology from the University of Ottawa, Ottawa, Ontario, Canada, and had post-doctoral training in clinical and cellular immunology at The Johns Hopkins University, Baltimore, Maryland, USA. He holds an Associate teaching position at the Johns Hopkins University Medical Institutions.
2021-05-18	Eyal Talor, Ph.D. 64 Chief Scientific Officer
2022-04-29	Eyal Talor, Ph.D. 65 Chief Scientific Officer
2023-04-10	Eyal Talor, Ph.D. 66 Chief Scientific Officer
2024-03-07	He received his Ph.D. in Microbiology and Immunology from the University of Ottawa, and had post-doctoral training in clinical and cellular immunology at The Johns Hopkins University.